• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Women's Health

Prasco launches generic NuvaRing

December 17, 2019 By Danielle Kirsh

prasco

Prasco this week said it launched its authorized generic NuvaRing. The generic etonogestrel/ethinyl vaginal ring is a small, flexible vaginal ring that is used by women as a form of birth control. The NuvaRing releases a continuous low dose of hormones for three weeks at a time. “We are proud to launch the authorized generic […]

Filed Under: Women's Health Tagged With: Merck, Prasco

FDA approves expanded indication for Liletta 6-year IUD

October 28, 2019 By Sean Whooley

Allergan, Medicines360

Medicines360 and its partner Allergan (NYSE:AGN) said today that the FDA approved Medicines360’s supplemental new drug application to extend the duration use of the Liletta intrauterine device for up to six years. The Liletta levonorgestrel-releasing intrauterine system now has the longest approved duration of use for a hormonal intrauterine device in the U.S., according to a […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Women's Health Tagged With: Allergan, FDA, Medicines360

FDA nixes Evoke Pharma’s gastro nasal spray

April 3, 2019 By Nancy Crotti

The FDA has rejected Evoke Pharma’s (NSDQ:EVOK) application for a metoclopramide nasal spray for diabetic women with gastroparesis. The Solana Beach, Calif. company’s stock price tumbled 40% on the news yesterday that the agency had found dosing inconsistencies in the pivotal pharmacokinetic study for the spray, Gimoti. In an earlier multi-disciplinary letter to the company, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Women's Health Tagged With: evokepharma, FDA

Study: Use of long-acting reversible contraception spiked after 2016 election

February 6, 2019 By Sarah Faulkner

In a study published this week in JAMA Internal Medicine, researchers reported that use of long-acting reversible contraception increased in the month following the 2016 presidential election. Adjusting for seasonal trends and patient characteristics, the researchers from Brigham & Women’s Hospital found that insertion of contraceptives such as intrauterine devices increased by 21.6% after the […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Women's Health Tagged With: Brigham & Women's Hospital

Inside Hologic’s evolving definition of women’s healthcare

August 13, 2018 By Sarah Faulkner

Hologic logo

Hologic (NSDQ:HOLX), known in the medtech industry for its mammography and diagnostics devices, is rethinking what it means to be a women’s healthcare company. The 6,000-person company wants to expand its reach to include products that care for women’s well-being, as well as their health – a concept that Dr. Edward Evantash honed when he led […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Women's Health Tagged With: hologic

Study: Heat-stable drug formulation offers new option to prevent postpartum bleeding

June 28, 2018 By Sarah Faulkner

Ferring Pharmaceuticals

Data from a collaboration between Ferring Pharmaceuticals, Merck (NYSE:MRK) and the World Health Organization showed that a heat-stable formulation of carbetocin is as effective as oxytocin for the prevention of excessive bleeding following vaginal birth. Millions of women are affected by postpartum hemorrhage every year, according to Ferring Pharmaceuticals. Traditionally, women are given oxytocin to prevent […]

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Wall Street Beat, Women's Health Tagged With: ferringpharmaceuticals, Merck, World Health Organization

Enteris BioPharma touts more Phase II data for oral endometriosis therapy

June 26, 2018 By Sarah Faulkner

Enteris BioPharma

Enteris BioPharma this week touted positive results from the final treatment arm of a Phase IIa trial of Ovarest, the company’s oral formulation of leuprolide. The drug is designed as an alternative to the injectable therapies available for people with endometriosis. Data from the last treatment arm of Enteris’ Phase IIa trial showed that the optimized […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Women's Health Tagged With: enterisbiopharma

On second try, TherapeuticsMD lands FDA nod for vaginal capsule

May 30, 2018 By Sarah Faulkner

TherapeuticsMD

TherapeuticsMD (NSDQ:TXMD) said today that it won FDA approval for its applicator-free estradiol vaginal capsule, TX-004HR. The soft-gel capsule is designed to treat moderate-to-severe vaginal pain experienced during sex, a symptom of vulvar and vaginal atrophy in women who have undergone menopause. The Boca Raton, Fla.-based company plans to market the product under the name ‘Imvexxy’. This […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat, Women's Health Tagged With: TherapeuticsMD

Allergan touts 5-year data for Liletta intrauterine contraceptive

May 1, 2018 By Sarah Faulkner

Allergan, Medicines360

Allergan (NYSE:AGN) and its nonprofit partner, Medicines360, touted five-year data today from an on-going pivotal trial of its intrauterine device, Liletta. The levonorgestrel-releasing contraceptive is approved in the U.S. to be used to prevent pregnancy for up to four years. The companies collected data from women who ranged from 16 – 45 years old. Two women, […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat, Women's Health Tagged With: Allergan, Medicines360

Qiagen wins FDA nod for point-of-care PartoSure test

April 20, 2018 By Sarah Faulkner

Qiagen

Qiagen (NYSE:QGEN) today touted the FDA’s approval of its PartoSure diagnostic test, designed to assess the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The non-invasive strip test detects placental alpha microglobulin-1 and can provide results in less than five minutes, according to Germany-based Qiagen. Beyond the company’s U.S. regulatory win, PartoSure […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat, Women's Health Tagged With: qiagen

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS